TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 170 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 6.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,271,216 | -86.5% | 254,051 | -76.9% | 0.01% | -87.9% |
| Q2 2023 | $16,865,971 | -54.8% | 1,098,045 | -33.8% | 0.06% | -56.1% |
| Q1 2023 | $37,303,916 | +204394.7% | 1,658,689 | +91.2% | 0.13% | +100.0% |
| Q4 2022 | $18,242 | -99.9% | 867,419 | -6.2% | 0.07% | -24.1% |
| Q3 2022 | $22,780,000 | -1.1% | 924,514 | -2.7% | 0.09% | +2.4% |
| Q2 2022 | $23,030,000 | +187.0% | 950,465 | +205.3% | 0.08% | +286.4% |
| Q1 2022 | $8,024,000 | +32.2% | 311,351 | +59.2% | 0.02% | +22.2% |
| Q4 2021 | $6,069,000 | – | 195,531 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Deep Track Capital, LP | 7,370,000 | $113,203,200 | 5.24% |
| Finepoint Capital LP | 761,721 | $11,700,035 | 4.05% |
| Kynam Capital Management, LP | 1,454,730 | $22,344,653 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 441,019 | $6,769,642 | 2.06% |
| MPM BioImpact LLC | 552,846 | $8,491,715 | 1.71% |
| ARMISTICE CAPITAL, LLC | 7,450,000 | $114,432,000 | 1.66% |
| SECTORAL ASSET MANAGEMENT INC | 435,313 | $6,686,408 | 1.12% |
| Octagon Capital Advisors LP | 495,000 | $7,603,200 | 1.06% |
| Orbimed Advisors | 2,118,100 | $32,534,016 | 0.59% |
| Rock Springs Capital Management LP | 1,527,720 | $23,465,779 | 0.56% |